InvestIdeas

not vested

by Dr. Check

Newly listed Suzhou Basecare Medical (2170) have caught the eye of investment expert Dr Check.

Suzhou Basecare Medical, which went public just two weeks ago, was oversubscribed 400 times for its initial public offering but the genetic testing solution provider’s share price went up by only 1.2 percent on its market debut from the IPO price of HK$27.36, Dr Check points out in a video on The Standard’s website and Facebook page.

Its shares have suddenly risen above HK$32 after hovering around its IPO price for five days, which may suggest the stock has been cornered and can be driven up, Dr Check says.

Source: The Standard

https://www.thestandard.com.hk/section- ... rth-a-look

vested

COMPANY PROFILE

Suzhou Basecare Medical Corp is an innovative platform of genetic testing solutions for assisted reproduction in China.

Its PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in in vitro fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA.

The NMPA registration of its PGT-A kit, in February 2020, as a Class III "innovative medical device," marked the birth of a regulated third-generation IVF market in China in which it is, to date, the only approved kit maker.

The Group is developing two other pre-implantation genetic testing, or PGT, products, namely, PGT-M and PGT-SR kits, which, together with its PGT-A kit, would form a complete test kit lineup to occupy the PGT field.

It is expected to obtain NMPA registration approval for these kits in 2022 and 2024, respectively.

In addition to its self-developed products, the Group also distributes DA8600, the only NGS sequencer approved by the NMPA for PGT, on which its test kits are designed to run, and a number of other test kits.

The Group sold a significant portion of products directly to hospitals and reproductive clinics. To a lesser extent, it also sold its genetic test kits to distributors, who in turn sell its products to hospitals and reproductive clinics.

Source: et.net

http://www.etnet.com.hk/www/eng/stocks/ ... code=02170

vested

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020

Revenue: +45%
Loss: RMB 878m

https://www1.hkexnews.hk/listedco/listc ... 002800.pdf

what is MPA registration ? what does it stands for ??

helios wrote:what is MPA registration ? what does it stands for ??

The National Medical Products Administration (NMPA) is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administration or CFDA).

Department of Medical Device Registration, responsible for pre-market approvals.

vested

Citi Initiates BASECARE-B (02170.HK) Buy with TP $40, Helped by CN Assisted Reproduction Mkt Expansion

Citigroup initiated BASECARE-B (02170.HK) at Buy with a $40 target.

The company has established an innovative genetic testing solution platform for assisted reproduction in Mainland China, boasting the first and only third-generation IVF genetic test kit (PGT-A) approved by NMPA.

As a PGT market pioneer, BASECARE-B will likely benefit from the robust segment growth.

Source: AAStocks Financial News

CLSA Capital Markets Limited acted as the sole sponsor in this transaction.

In this IPO, Basecare received strategic cornerstone investments from OrbiMed, Lake Bleu Prime, CRF Investment Holdings, Affin Hwang Asset Management, WinTwin Capital, Foresight Funds, and IvyRock Asset Management.

https://www.globallegalchronicle.com/su ... -kong-ipo/

vested

BASECARE(2170)

by Louis Wong

Analysis:-

Suzhou Basecare Medical Corporation (2170) is an innovative platform of genetic testing solutions for assisted reproduction in China.

The Company`s mission is to help more families have healthy babies.

Its PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in in vitro fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA.

It is developing two other pre-implantation genetic testing, or PGT, products, namely, PGT-M and PGT-SR k its, which, together with our PGT-A kit, would form a complete test kit lineup to occupy the PGT field.

The Group expects to obtain NMPA registration approval for PGT-M and PGT-SR kits in 2022 and 2024, respectively, which will would further its dominance in the third-generation IVF genetic test kit market in China. (I do not hold the above stock)

Strategy：
Buy-in Price: $26.50, Target Price: $29.00, Cut Loss Price: $25.00

Source: Phillips

vested

1H, 2021

Revenue: +56%
Loss: RMB 42m from RMB 808m

https://www1.hkexnews.hk/listedco/listc ... 001210.pdf

vested

Annual Report

Revenue: +30%
Losses: RMB 105m
Cash: RMB 1.5b

http://iis.aastocks.com/20220427/10232393-0.PDF